The Anti-Longevity PlaybookGet the Playbook
Evidence Review
Tirzepatide (Mounjaro / Zepbound)
Verdict
PromisingEvidence Tier
A
Strong evidence
Human Studies
Yes — ongoing
Typical Cost
$300-1,000/mo
Tirzepatide is a dual GLP-1/GIP agonist showing even greater weight loss than semaglutide in head-to-head data. Cardiovascular outcome trials are ongoing. Given the strength of the GLP-1 class data, tirzepatide is likely to show similar cardiovascular benefits, potentially even stronger. This is the most exciting drug class in metabolic medicine.
The full evidence review — including why the dual-agonist approach may outperform semaglutide and what the pending trials will tell us — is in Section 9 (GLP-1/GIP Agonists) of The Anti-Longevity Playbook.
Reviewed by Dr. Ramy Khalil, MD · Double Board-Certified Internal Medicine · Last updated March 2026
Is tirzepatide better than semaglutide?
Tirzepatide shows greater weight loss than semaglutide in head-to-head data. Cardiovascular outcome trials are ongoing, but the dual-agonist mechanism is promising.
Free Chapter
Want the full picture?
Start with a free chapter.
Read the first chapter of The Anti-Longevity Playbook free — including the intervention with stronger mortality data than Tirzepatide.
More from GLP-1/GIP Agonists
Browse All Evidence Reviews
30+ longevity interventions reviewed by a physician against the primary literature.
ExerciseStatinsApoB TestingNMNNMN vs. NR — Which Is Better?ResveratrolRapamycinMetformin for LongevityBPC-157PeptidesCold Plunge / Cold ExposureSaunaSleepTestosterone Replacement TherapyGrowth HormoneContinuous Glucose MonitorFull-Body MRI ScreeningBiological Age TestsSemaglutideTirzepatideIntermittent FastingCaloric RestrictionBerberineOmega-3 Fatty AcidsVitamin DMagnesiumCoQ10SpermidineCreatineSocial ConnectionAlcohol